Who Owns INHIBIKASE THERAPEUTICS INC (IKT)? -- Institutional Holders (2026-06-30)

117 institutions reported holding $239.8M of INHIBIKASE THERAPEUTICS INC (IKT) in SEC 13F filings for 2026-06-30. Largest institutional holders: Sands Capital Alternatives, LLC ($26.4M), Soleus Capital Management, L.P. ($22.1M), Trails Edge Capital Partners, LP ($18.4M), Fairmount Funds Management LLC ($17.5M), BlackRock, Inc. ($15.8M). Source: SEC Form 13F.

RankInstitutionValueSharesChange
1Sands Capital Alternatives, LLC$26.4M13.0MHold
2Soleus Capital Management, L.P.$22.1M10.9MHold
3Trails Edge Capital Partners, LP$18.4M9.1MAdded
4Fairmount Funds Management LLC$17.5M8.6MHold
5BlackRock, Inc.$15.8M7.8MAdded
6ADAR1 Capital Management, LLC$15.0M7.4MAdded
7VANGUARD GROUP INC$13.0M6.4MAdded
8Blackstone Inc.$12.1M5.9MHold
9Siren, L.L.C.$11.9M5.8MHold
10Commodore Capital LP$11.0M5.4MHold
11MILLENNIUM MANAGEMENT LLC$8.2M4.0MAdded
12Saturn V Capital Management LP$7.9M3.9MAdded
13Kalehua Capital Management LLC$7.8M3.8MTrimmed
14Spruce Street Capital LP$7.3M3.6MHold
15Squadron Capital Management LLC$6.1M3.0MTrimmed
16Nantahala Capital Management, LLC$5.5M2.7MHold
17GEODE CAPITAL MANAGEMENT, LLC$5.3M2.6MAdded
18STATE STREET CORP$3.9M1.9MAdded
19SummitTX Capital, L.P.$3.6M1.8MAdded
20Integral Health Asset Management, LLC$2.7M1.4MHold
21NORTHERN TRUST CORP$1.8M878,585Added
22TWO SIGMA INVESTMENTS, LP$1.6M806,264Trimmed
23SPHERA FUNDS MANAGEMENT LTD.$1.3M649,309New
24Kennondale Capital Management LLC$1.1M565,983New
25Pathstone Holdings, LLC$1.0M510,596New

Source: SEC Form 13F filings · as of 2026-06-30